Volume 14, Issue 7, Pages 627-637 (June 2013) Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial  Thomas Crosby, FRCR, Christopher N Hurt, MSc, Stephen Falk, MD, Simon Gollins, FRCR, Somnath Mukherjee, FRCP, John Staffurth, MD, Ruby Ray, PhD, Nadim Bashir, BSc, John A Bridgewater, FRCP, J Ian Geh, FRCP, Prof David Cunningham, FRCP, Prof Jane Blazeby, MD, Rajarshi Roy, FRCR, Prof Tim Maughan, FRCP, Gareth Griffiths, MSc  The Lancet Oncology  Volume 14, Issue 7, Pages 627-637 (June 2013) DOI: 10.1016/S1470-2045(13)70136-0 Copyright © 2013 Elsevier Ltd Terms and Conditions

Figure 1 Trial profile The Lancet Oncology 2013 14, 627-637DOI: (10.1016/S1470-2045(13)70136-0) Copyright © 2013 Elsevier Ltd Terms and Conditions

Figure 2 Kaplan-Meier curves of overall survival by treatment group CRT=chemoradiotherapy. The Lancet Oncology 2013 14, 627-637DOI: (10.1016/S1470-2045(13)70136-0) Copyright © 2013 Elsevier Ltd Terms and Conditions

Figure 3 Hazard ratio plots for overall survival, by baseline characteristics Survival data are median number of months (95% CI) in all patients. Positions of squares show hazard ratio of death in the CRT plus cetuximab group compared with death in the CRT only group; the area of each square represents the amount of information (ie, the number of patients) in each category. Lines show 95% CIs. CRT=chemoradiotherapy. NC=not calculable because of small numbers of patients. The Lancet Oncology 2013 14, 627-637DOI: (10.1016/S1470-2045(13)70136-0) Copyright © 2013 Elsevier Ltd Terms and Conditions

Figure 4 Physical functioning score from QLQ-C30 in each treatment group at five timepoints over 52 weeks The number of patients shows the amount who completed QLQ-C30 at each timepoint. A higher score indicates better function. Bars show 95% CI. QLQ-C30=European Organisation for Research and Treatment of Cancer's Quality of Life Questionnaire C30. The Lancet Oncology 2013 14, 627-637DOI: (10.1016/S1470-2045(13)70136-0) Copyright © 2013 Elsevier Ltd Terms and Conditions

Figure 5 Eating restrictions score from QLQ-OES18 in each treatment group at five timepoints over 52 weeks The number of patients shows the amount who completed QLQ-OES18 at each timepoint. A higher score indicates a greater number of problems. Bars show 95% CI. QLQ-OES18=European Organisation for Research and Treatment of Cancer's Quality of Life Questionnaire OES18. The Lancet Oncology 2013 14, 627-637DOI: (10.1016/S1470-2045(13)70136-0) Copyright © 2013 Elsevier Ltd Terms and Conditions